PRTA shares drop 22% after ending birtamimab development as a phase III study fails to meet primary or secondary endpoints in AL amyloidosis.

Prothena Corporation’s Phase III AFFIRM-AL trial of birtamimab in individuals with amyloid light-chain (AL) amyloidosis ...

Prothena has already discontinued the development of birtamimab, and anticipates further spending cuts, including workforce ...

Prothena has made the decision to discontinue the AFFIRM-AL trial, including the open-label extension portion.

Prothena Corporation plc (NASDAQ:PRTA) released data from the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in ...

Prothena Corporation plc's phase 3 trial failure in AL Amyloidosis was a setback, but Alzheimer's & Parkinson's data could ...

Prothena (PRTA) stock drops as a late-stage trial for the company's lead candidate fails, prompting Oppenheimer and Jefferies ...

Prothena has buried birtamimab for the second time. A phase 3 trial of the anti-amyloid antibody in the rare disease AL ...

Prothena Corporation (NASDAQ:PRTA) is a clinical-stage neuroscience company that discovers and develops novel therapies for ...

At St. Clair Health, a community health system in Pittsburgh, where Dr. Pray was working to build up an organized heart ...

What: Erlanger Trauma Services will host its annual Trauma Symposium at the Chattanooga Convention Center on Thursday, May 22 ...

Transthyretin amyloidosis (ATTR) is a condition caused by TTR protein misfolding and amyloid deposition, particularly in the ...